In a randomised trial of 100 eyes, standard corneal cross-linking halted keratoconus progression and improved several measures, while corneal steepening continued in controls.
Two phase 3 trials compared faricimab with aflibercept in neovascular AMD. Faricimab produced comparable visual-acuity outcomes and allowed longer injection intervals for some patients.
In the ACCESS trial, autonomous AI eye examinations were performed within a diabetes clinic. This pathway increased screening completion and follow-up compared with a conventional referral.